Zoetis Inc. and Teva Pharmaceutical Industries Limited: A Detailed Gross Profit Analysis

Zoetis vs. Teva: A Decade of Profit Shifts

__timestampTeva Pharmaceutical Industries LimitedZoetis Inc.
Wednesday, January 1, 2014110560000003068000000
Thursday, January 1, 2015113560000003027000000
Friday, January 1, 2016118590000003222000000
Sunday, January 1, 2017108250000003532000000
Monday, January 1, 201882960000003914000000
Tuesday, January 1, 201975360000004268000000
Wednesday, January 1, 202077250000004618000000
Friday, January 1, 202175940000005473000000
Saturday, January 1, 202269730000005626000000
Sunday, January 1, 202376460000005834000000
Monday, January 1, 202480640000006537000000
Loading chart...

Data in motion

A Tale of Two Pharmaceutical Giants: Zoetis Inc. vs. Teva Pharmaceutical Industries Limited

In the ever-evolving pharmaceutical landscape, Zoetis Inc. and Teva Pharmaceutical Industries Limited stand as titans, each with a unique trajectory in gross profit over the past decade. From 2014 to 2023, Zoetis Inc. has seen a remarkable growth of nearly 90% in its gross profit, reflecting its robust market strategies and expanding product portfolio. In contrast, Teva Pharmaceutical has experienced a decline of approximately 31%, highlighting the challenges it faces in a competitive market.

Key Insights

  • Zoetis Inc.: Starting at $3 billion in 2014, Zoetis's gross profit surged to nearly $5.8 billion by 2023, showcasing consistent growth.
  • Teva Pharmaceutical: Peaking at $11.9 billion in 2016, Teva's gross profit fell to around $7.6 billion in 2023, indicating a need for strategic realignment.

This analysis underscores the dynamic nature of the pharmaceutical industry and the importance of strategic agility.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025